5-HT3 receptor antagonists and anxiety; A preclinical and clinical review

European Neuropsychopharmacology

Volumn 10, Issue 2, 2000, Pages 77-95

  Olivier, Berend ^a,b,c   Van Wijngaarden, Ineke ^d   Soudijn, Willem ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PSYCHOGENICS INC   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

5 HT(1A) receptor; 5 HT3 receptor; 5 HT3 receptor antagonists; Adult ultrasonic vocalization; Animal models; Anxiety; Benzodiazepines; Conditioned place preference; Conflict; Defeat induced analgesia; Defensive burying; Drug discrimination; Elevated plus maze; Generalized anxiety disorder; Light dark exploration; Panic disorder; Periaquaductal gray stimulation; Potentiated startle; Social interaction; Stress induced hyperthermia; Ultrasonic pup vocalization

Indexed keywords

2 CYCLOPROPYLMETHOXY N (8 METHYL 8 AZABICYCLO[3.2.1]OCTAN 3 YLCARBAMOYL)BENZAMIDE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BEMESETRON; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BUSPIRONE; DIAZEPAM; DOLASETRON MESILATE; FLESINOXAN; GEPIRONE; GRANISETRON; IPSAPIRONE; ITASETRON; ONDANSETRON; SEROTONIN 1A AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON; ZACOPRIDE;

ANIMAL MODEL; ANXIETY NEUROSIS; BINDING AFFINITY; BRAIN REGION; CONFLICT; DEFENSIVE BEHAVIOR; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; ELECTROSTIMULATION; FEAR; HUMAN; LIGHT ADAPTATION; MAZE TEST; NONHUMAN; PANIC; PIGEON; PRIORITY JOURNAL; REBOUND; REVIEW; SOCIAL BEHAVIOR; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DISEASE MODELS, ANIMAL; HUMANS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS;

EID: 0033994306     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00065-6     Document Type: Review

References (230)

1. Allin J.T., Banks E.M. Functional aspects of ultrasound production by infant albino rats (Rattus norvegious). Anim. Behav. 20:1972;175-185.
2. Andrews N., File S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 235:1993;109-112.
3. 2 agonists in rats. Pharmacol. Toxicol. 64:1989;165-172.
4. Aron C., Simon P., Larousse C., Boissier J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology. 10:1971;459-469.
5. 3 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology. 117:1995;137-148.
6. 3 antagonist, ondansetron, in panic disorder (in press).
7. 3 receptor ligands. Neurosci. Biobehav. Rev. 16:1992;107-113.
8. 3 receptor antagonists. Pharmacol. Biochem. Behav. 37:1990;717-727.
9. 3 receptor antagonist, on cognition in rodents and primates. Pharmacol. Biochem. Behav. 35:1990;955-962.
10. Barrett J.E. Animal behavioral models in the analysis and understanding of anxiolytic drugs at serotonin receptors. Olivier B., Mos J., Slangen J.L. Animal models in psychopharmacology. 1991;37-52 Birkhäuser, Basel.
11. 3 antagonists and benzodiazepines; their comparative behavioural pharmacology. 1991;59-105 Wiley, Chichester.
12. Barrett J.E., Witkins J.M., Mansbach R.S., Skolnick P., Weissman B.A. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. J. Pharmacol. Exp. Ther. 238:1986;1009-1013.
13. Barros H.M.T., Miczek K.A. Withdrawal from oral cocaine in rats: ultrasonic vocalizations and tactile startle. Psychopharmacology. 125:1996;379-384.
14. S receptor subunit. Mol. Pharmacol. 48:1995;1054-1062.
15. 3 receptor agonist does not alter the ethanol-induced conditioned taste aversion in rats. Pharmacol. Biochem. Behav. 59:1998;975-980.
16. 3 receptor antagonist, in two models of anxiety. In: Serotonin: 5-hydroxytryptamine-CNS receptors and brain function, Abstract, p. 113.
17. 3 receptor antagonist in two animal models of anxiety. Eur. J. Pharmacol. 218:1992;327-334.
18. Blanchard R.J., Blanchard D.C., Agullana R., Weiss S.M. Twenty-two kHz alarm cries to presentation of a predator, by laboratory rats living in visible burrow systems. Physiol. Behav. 50:1991;967-972.
19. Blandina P., Goldfarb J., Craddock-Royal B., Green J.P. Release of endogenous dopamine by stimulation of 5-hydroxytryptamine 3 receptors in rat striatum. J. Pharmacol. Exp. Ther. 251:1989;803-809.
20. 4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. Mol. Pharmacol. 37:1990;408-411.
21. 3 receptor. J. Neurochemistry. 64:1995;1401-1405.
22. Boissier J.R., Simon P., Aron C. A new method for rapid screening of minor tranquilizers in mice. Eur. J. Pharmacol. 4:1968;145-151.
23. 3 antagonist, in animal models of anxiety. Pharmacol. Res. 27:1993;151-163.
24. Borsini F., Lecci A., Volterra G., Meli A. A model to measure anticipatory anxiety in mice? Psychopharmacology. 98:1989;207-211.
25. Bovier P., Broekkamp C.L.E., Lloyd K.G. Enhancing GABAergic transmission reverses the aversive state in rats induced by electrical stimulation of the periaqueductal gray region. Brain Res. 248:1982;313-320.
26. Bradley P.B., Engel G., Feniuk W., Fozard J.R., Humphrey P.A., Middlemiss D.N., Mylecharane E.J., Richardson B.P., Saxena P.R. Proposals for the classification and nomenclature of functional receptors for 5-HT. Neuropharmacology. 25:1986;563-576.
27. Broekkamp C.L., Jenck F. The relationship between various animal models of anxiety, fear-related psychiatric symptoms and response to serotonergic drugs. Bevan P., Cools A.R., Archer T. Behavioural Pharmacology of 5-HT. 1989;321-335 Lawrence Erlbaum, Hillsdale, New Jersey.
28. Broekkamp C.L., Rijk H.W., Joly-Gelouin D., Lloyd K.L. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur. J. Pharmacol. 126:1986;223-229.
29. Broekkamp C.L.E., Berendsen H.H.G., Jenck F., Van Delft A.M.L. Animal models for anxiety and response to serotonergic drugs. Psychopathology. 22:(suppl 1):1989;2-12.
30. Carli M., Prontera C., Samanin R. Evidence that central 5-hydroxy-tryptaminergic neurones are involved in the anxiolytic activity of buspirone. Br. J. Pharmacol. 96:1989;829-836.
31. 3 receptor antagonists increase rates of punished responding in rats. Pharmacol. Biochem. Behav. 52:1995;671-676.
32. Colpaert F.C., Koek W. 5-HT receptor ligands and conflict behavior. Second Polish-Swedish Symposium on Neurotransmitters and neuropharmacology, Zakopane :1991;5.
33. Cooper S.J. Benzodiazepines as appetite enhancing compounds. Appetite. 1:1980;7-19.
34. 3 receptor antagonist, RS-42358-197, in animal models of anxiety. Eur. J. Pharmacol. 234:1993;91-99.
35. Costall B., Domeney A.M., Gerrard P.A., Kelly M.E., Naylor R.J. Zacopride: anxiolytic profile in rodent and primate models of anxiety. J. Pharm. Pharmacol. 40:1988;302-305.
36. Costall B., Domeney A.M., Gerrard P.A., Naylor R.J. A primate model for the assessment of anxiolytic drug action. Br. J. Pharmacol. 92:1988;881-894.
37. Costall B., Domeney A.M., Hendrie C.A., Kelly M.E., Naylor R.J., Tyers M.B. The anxiolytic activity of GR 38032F in the mouse and marmoset. Br. J. Pharmacol. 90:1987;257P.
38. Costall B., Domeney A.M., Kelly M.E., Naylor R.J. Pharmacological models in the development of antipsychotic drugs-new strategies. Olivier B., Mos J., Slangen J.L. Animal models in psychopharmacology. 1991;253-263 Birkhäuser, Basel.
39. 3 antagonist, GR 38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br. J. Pharmacol. 92:1987;881-894.
40. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Oakley N.R., Onaivi E.S., Tyers M.B. The effects of ondansetron (GR 38032F) in rats and mice treated subchronically with diazepam. Pharmacol. Biochem. Behav. 34:1989;769-778.
41. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., Tyers M.B. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol. Biochem. Behav. 36:1990;97-104.
42. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., Tyers M.B. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol. Biochem. Behav. 36:1990;339-344.
43. 3 receptor antagonists in the elevated X-maze. J. Psychopharmacol. 3:1989;10P.
44. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Tomkins D.M. Exploration of mice in a black and white box: validation as a model of anxiety. Pharmacol. Biochem. Behav. 32:1989;777-785.
45. 3 antagonists and benzodiazepines: their comparative behavioural pharmacology. 1991;133-157 Wiley, Chichester.
46. Crawley J.N. Neuropharmacological specificity of a simple animal model for the behavioural actions of benzodiazepines. Pharmacol. Biochem. Behav. 15:1981;695-699.
47. Crawley J.N., Goodwin F.K. Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 13:1980;167-170.
48. 2 receptors. Psychopharmacology. 93:1987;502-506.
49. Cuomo V., Ciagiano R., Salvia M.A. Ultrasonic vocalization in response to unavoidable aversive stimuli in rats: effects of benzodiazepines. Life Sci. 43:1988;485-491.
50. 3 receptor antagonists, BRL 43694 and ICS 205-930, under circumstances of high and low light intensity. Neuropharmacology. 29:1990;515-520.
51. 3 antagonist, BRL43694 (Granisetron) on behaviour during social interactions in female and male mice. Neuropharmacology. 30:1991;299-306.
52. 3 antagonist, ICS 205-930, on behaviour of mice during social encounters. Br. J. Pharmacol. 96:1989;12P.
53. 3 receptor antagonist BRL 43694; effects on reflex epilepsy and social behaviour of the Mongolian gerbil. Psychopharmacology. 101:1990;244-249.
54. 3 antagonists granisetron and BRL 46470, on the behaviour of intruder mice. Br. J. Pharmacol. 104:1991;254P.
55. Davis M. Effect on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology. 62:1979;1-7.
56. Davis M. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav. Neurosci. 100:1986;814-824.
57. Davis M., Cassella J.V., Kehne J.H. Serotonin does not mediate anxiolytic effect of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone. Psychopharmacology. 94:1988;14-20.
58. Davis M., Redmond D.E. Jr., Baraban J.M. Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm. Psychopharmacology. 65:1979;111-118.
59. Davis S.F., Moore S.A., Cowen C.L., Thurston D.K., Maggio J.C. Defensive burying in the Mongolian gerbil (Meriones unguiculatus) as a function of size and shape of the test chamber. Anim. Learn. Behav. 10:1982;516-520.
60. De Boer S.F., Van der Gugten J., Slangen J.L. Behavioural and hormonal indices of anxiolytic and anxiogenic drug action in the shock prod defensive burying/avoidance paradigm. Olivier B., Mos J., Slangen J.L. Animal Models in Psychopharmacology. 1991;81-96 Birkhäuser, Basel.
61. 3 compounds in a drug discrimination model. Pharmacol. Biochem. Behav. 54:1996;533-540.
62. De Vrij J., Benz U., Schreiber R., Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur. J. Pharmacol. 249:1993;331-339.
63. Dourish C.T., Hutson P.H., Kennett G.A., Curzon G. 8-OH-DPAT induced hyperphagia: its neural basis and possible therapeutic relevance. Appetite (Suppl). 7:1986;127-140.
64. 3 antagonists ondansetron, zacopride, 3a-tropanyl-1H-indole-3-carboxylic acid ester, and 1aH, 3a, 5aH-tropan-3-yl-3,5-dichlorobenzoate. Drug Devl. Res. 23:1991;289-300.
65. Eikelboom R. Learned anticipatory rise in body temperature due to handling. Physiol. Behav. 37:1986;649-653.
66. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Meth. 2:1980;219-238.
67. File S.E. Animal models for predicting clinical efficacy of anxiolytic drugs. Neuropsychobiology. 13:1985;55-62.
68. 3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. Psychopharmacology. 99:1989;248-251.
69. File S.E., Johnston A.L., Pellow S. Effects of compounds acting at CNS 5-hydroxytryptamine systems on anxiety in the rat. Brit. J. Pharmacol. 90:1987;265P.
70. 3) receptor antagonists. Pol. J. Pharmacol. Pharm. 44:1992;261-269.
71. Fletcher P.J., Davis M. Effects of 8-OH-DPAT, buspirone and ICS 205-930 on feeding in a novel environment: comparisons with chlordiazepoxide and FG 7142. Psychopharmacology. 102:1990;301-308.
72. Fozard J.R., Mobarek Ali A.T.M. Blockade of neuronal tryptamine receptors by metoclopramide. Br. J. Pharmacol. 49:1978;109-112.
73. Fozard J.R., Mobarek Ali A.T.M., Newgrosh G. Blockade of serotonin receptors on autonomic neurones by (-) cocaine and some related compounds. Eur. J. Pharmacol. 59:1979;195-210.
74. Freeman A.M., Westphal J.R., Norris G.T., Roggero B.A., Webb P.B., Freeman K.L., Rush J.A., Hearne E.M., Evoniuk G. Efficacy of ondansetron in the treatment of generalized anxiety disorder. Depression Anxiety. 5:1997;140-141.
75. Fundaro A. Pinch-induced catalepsy in mice: a usefull model to investigate antidepressant or anxiolytic drugs. Progr. Neuro-Psychopharmacol. Biol. Psychiat. 22:1998;147-158.
76. Gaddum J.H., Picarelli Z.P. Two kinds of tryptamine receptor. Br. J. Pharmacol. 12:1957;323-328.
77. Gardner C.R. Pharmacological studies on the role of serotonin in animal models of anxiety. Green A.R. Neuropharmacology of serotonin. 1985;281-325 Oxford University Press, Oxford.
78. Gardner C.R., Budhram P. Effects of agents which interact with central benzodiazepine binding sites on stress-induced ultrasounds in rat pups. Eur. J. Pharmacol. 134:1987;275-283.
79. 4 receptor antagonists. Med. Res. Rev. 17:1997;163-214.
80. Geller I., Seifter J. The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia. 1:1960;482-492.
81. Gleeson S., Ahlers S.T., Mansbach R.S., Foust J.M., Barrett J.E. Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J. Pharmacol. Exp. Ther. 250:1989;809-817.
82. Glenn B., Green S. Anxiolytic profile of GR 38032F in the potentiated startle paradigm. Behav. Pharmacol. 1:1989;91-94.
83. Glennon R.A., Westkaemper R.B., Bartyzel P. Medicinal chemistry of serotonergic agents. Peroutka S.J. Serotonin receptor subtypes: basic and clinical aspects. 1991a;19-64 Wiley-Liss, New York.
84. 3 serotonin agonists as discriminative stimuli. Soc. Neurosci. Abstr. 17:(1):1991b;601.
85. 3 agonist 2-methyl serotonin as a training drug in drug discrimination studies. Pharmacol. Biochem. Behav. 41:1992;361-364.
86. Goa K.L., Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 32:1986;114-129.
87. Goldberg H.L., Finnerty R.J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry. 136:1979;1184-1187.
88. 3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats. Eur. J. Pharmacol. 185:1990;179-186.
89. 3 Receptors. Pharmacochemistry Library 27. 1997;221-257 Elsevier Science Publishers, Amsterdam.
90. Graeff F.G. The anti-aversive action of minor tranquilizers. Tr. Pharmacol. Sci. 5:1984;230-233.
91. Graeff F.G., Brandao M.L., Audi E.A., Schuetz M.T. Modulation of the brain aversive system by GABA-ergic and serotonergic mechanisms. Behav. Brain Res. 21:1986;65-72.
92. 3 receptor antagonists. Psychopharmacology. 104:1991;451-456.
93. 3 antagonists to block ethanol discrimination: effect of route of administration. Alcohol Clin. Exp. Res. 17:1993;497-503.
94. 3 receptor antagonists: Clinical pharmacology and therapeutic applications. Drugs. 53:1997;20-39.
95. Griebel G. 5-hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmac. Ther. 65:1995;319-395.
96. Griebel G., Rodger R.J., Perrault G., Sanger D.J. Risk assessment behaviour: evaluation of utility in the study of 5-HT related drugs in the rat elevated plus-maze test. Pharmacol. Biochem. Behav. 57:1997;817-827.
97. Hall S.T., Ceuppens P.R. A study to evaluate the effects of ondansetron on psychomotor performance after repeated oral dosing in healthy subjects. Eur. J. Pharmacol. 104:1991;86-90.
98. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedeberg's. Arch. Pharmacol. 327:1984;1-5.
99. Hård E., Engel J., Musi B. The ontogeny of defensive reactions in the rat: influence of the monoamine transmission systems. Scand. J. Psychol. Suppl. 1:1982;90-96.
100. Heynen A.J., Sainsbury R.S., Montoya C.P. Cross-species responses in the defensive burying paradigm: a comparison between Long-Evans rats (Rattus norvegicus). Richardson's ground squirrels (Spermophilus richardsonii), and Thirteen-lined ground squirrels (Catellus tridecemlineatus). J. Comp. Psychol. 103:1989;184-190.
101. 3 receptor antagonists. Psychopharmacology. 104:1991;545-551.
102. Hijzen T.H., Houtzager S.W., Joordens R.J.E., Olivier B., Slangen J.L. Predictive validity of the potentiated startle response as a behavioral model for anxiolytic drugs. Psychopharmacology. 118:1995;150-154.
103. Hudson B.B. One-trial learning in the domestic rat. Genetic Psychol. Monogr. 41:1950;99-145.
104. Jackson R.L., Garbin C.P., Hollingsworth E.M. Defensive burying of aversive fluids in rats: the possible role of odor. Learn Motivation. 15:1984;85-105.
105. 3 receptors. Psychopharmacology. 97:1989;489-495.
106. 1C) receptors on periaqueductal gray aversion. Eur. J. Pharmacol. 161:1989;219-221.
107. 1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats. Psychopharmacology. 100:1990;372-376.
108. Johanson C.E., Barrett J.E. The dricriminative stimulus effects of cocaine in pigeons. J. Pharmacol. Exp. Ther. 267:1995;1-8.
109. 3 receptor antagonists on the discriminative stimulus properties of morphine in rats. Psychopharmacology. 112:1993;111-115.
110. 3 receptor expression in the central and peripheral nervous system-an in situ hybridization study. Soc. Neurosci. Abstr. 19:1993;632.
111. 3-receptor antagonist. Br. J. Pharmacol. 93:1988;985-993.
112. Joordens R.J.E., Hijzen T.H., Peeters B.W.M.N., Olivier B. Fear-potentiated startle response is remarkably similar in two laboratories. Psychopharmacology. 126:1996;104-109.
113. 1A receptor antagonists and their interaction in the fear-potentiated startle response paradigm. Psychopharmacology. 139:1998;383-390.
114. Kaltwasser M.T. Acoustic startle-induced ultrasonic vocalizations in the rat: a novel animal model of anxiety? Behav. Brain Res. 3:1991;133-137.
115. Kehne J.H., Cassella J.V., Davis M. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology. 94:1988;8-13.
116. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P., Palfreyman M.G. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur. J. Pharmacol. 193:1991;283-292.
117. 3 antagonist. J. Psychopharmacol. 4:1990;291.
118. Ketelaars C.E.J., Bollen E.L., Rigter H., Bruinvels J. GABA-B receptor activation and conflict behaviour. Life Sci. 42:1988;933-942.
119. Ketelaars C.E.J., Bruinvels B. Extinction of conflict behaviour. In: Olivier B., Mos J., Slangen J.L. Animal Models in Psychopharmacology. 1991;103-106 Birkhäuser, Basel.
120. Kilfoil T., Michel A., Montgomery D., Whiting R.L. Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice. Neuropharmacology. 28:1989;901-905.
121. 3 receptors. Med. Res. Rev. 10:1990;441-475.
122. 3 receptors in rat brain using radioligand binding. Nature. 330:1987;746-748.
123. King, F.D., 1994. 5-hydroxytryptamine-3-receptor antagonists. In: King, F.D., Jones, B.J., Sanger, G.J. (Eds), CRC: Boca Raton FLA, pp. 1-44.
124. Koetzner K., Mastropaolo J., Deutsch S.I. Facilitating role of m-chlorophenyl-biguanide in a cocaine discrimination. Pharmacol. Biochem. Behav. 52:1995;815-818.
125. Kshama D., Hrishikeshavan H.J., Shanbhogue R., Manonyedi U.S. Modulation of baseline behavior in rats by putative serotonergic agents in three ethoexperimental paradigms. Behav. Neural. Biol. 54:1990;234-253.
126. th World Congress Biol. Psychiatry :1991;17-19.
127. Lane J.D., Pickering C., Hooper M., Fagan K., Tyers M.B., Emmett-Oglesby M.B. Failure of ondansetron to block discriminative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend. 30:1992;151-162.
128. 3 receptors. 1992;157-187 Academic Press, London.
129. Lecci A., Borsini F., Mancinelli A., D'Aranno V., Stasi M.A., Volterra G., Meli A. Effect of serotonergic drugs on stress-induced hyperthermia (SIH) in mice. J. Neural. Transm. 2:1990;219-230.
130. Lecci A., Borsini F., Volterra G., Meli A. Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology. 101:1990;255-261.
131. Lecrubier Y., Puech A.J., Azcona A., Bailey P.E., Lataste X. A randomized double-blind placebo controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology. 112:1993;129-133.
132. Lee C.R., Plosker G.L., McTavish D. Tropisetron. A review of its pharma-codynamic and pharmacokinetic properties and therapeutic potential as an antiemetic. Drugs. 46:1993;925-943.
133. Leigh T.J., Link C.G.G., Fell G.L. Effects of granisetron and lorazepam, alone and in combination, on psychometric performance. Biol. Psychiatry. 29:1991;602S.
134. 2 membrane-spanning region lines the ion channel pore of the nicotinic receptor. Science. 242:1988;1578-1581.
135. Lister R.G. Ethologically-based models of anxiety disorders. Pharmac. Ther. 46:1990;321-340.
136. 3 receptor, a serotonin-gated ion channel. Science. 254:1991;432-437.
137. Mathew R.J., Wilson W.H. Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. Psychiatry. Res.; Neuro imaging. 40:1991;125-134.
138. 3 antagonist, ondansetron, on the behavioural and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology. 17:1997;360-369.
139. A and 5-HT anxiolytics. Psychopharmacology. 121:1995;38-56.
140. Miczek K.A., Vivian J.A. Automatic quantification of withdrawal from 5-day diazepam in rats: ultrasonic distress vocalizations and hyperreflexia to acoustic startle stimuli. Psychopharmacology. 110:1993;379-382.
141. 3 receptor antagonist. CNS Drug Res. 2:1996;269-293.
142. 3 agonist-effects of zacopride in the ferret. Brit. J. Pharmac. 101:1990;560.
143. 3 receptor antagonist. CNS Drug Res. 2:1996;269-293.
144. th World Congress Biol. Psychiatry :1991;13-15.
145. 3 receptor agonist mCPBG in the social interaction test of anxiety. Br. J. Pharmacol. 104:1991;252P.
146. 3 receptor: heterogeneity in distribution and function among species. Mol. Pharmacol. 48:1995;407-416.
147. Molewijk H.E., Hartog K., Van der Poel A.M., Mos J., Olivier B. Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology. 128:1996;31-38.
148. Molewijk H.E., Van der Poel A.M., Mos J., Van der Heyden J.A.M., Olivier B. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology. 117:1995;32-40.
149. 3 receptor antagonists. GR 38032F and BRL 24924 on anxety in socially isolated rats. Br. J. Pharmacol. 97:1989;457P.
150. Mos J., Olivier B. Ultrasonic vocalizations by rat pups as an animal model for anxiolytic activity: effects of serotonergic drugs. Bevan P., Cools A.R., Archer T. Behavioural Pharmacology of 5-HT. 1989;361-366 Lawrence Erlbaum, Hillsdale, New Jersey.
151. Mos J., Olivier B. Behavioural and neuropharmacological aspects of maternal aggression in rodents. Aggr. Behav. 16:1990;145-163.
152. 3 antagonists in animal models for aggression, anxiety and psychosis. Bevan P., Cools A.R., Archer T. Behavioural Pharmacology of 5-HT. 1989;389-395 Lawrence Erlbaum, New Jersey.
153. Moser P.C. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology. 99:1989;48-53.
154. 3 receptor antagonists on the discriminative stimulus properties of amphetamine. Eur. J. Pharmacol. 212:1992;271-276.
155. Nader M.A., Hoffman S., Gleeson S., Barrett J.E. Further characterisation of the discriminative stimulus effects of buspirone using monoamine agonists and antagonists in the pigeon. Behav. Pharmacol. 1:1989;57-67.
156. Nastiti K., Benton D., Brain P.F. The effects of compounds acting at the benzodiazepine receptor complex on the ultrasonic calling of mouse pups. Behav. Pharmacol. 2:1991;121-128.
157. 3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? J. Pharmacol. Exp. Ther. 268:1994;248-268.
158. Njung'e K., Handley S.L. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br. J. Pharmacol. 104:1991;105-112.
159. 3 receptor mediation is involved etiologically in the psychological stress lesion in the stomach of the mouse. J. Pharmacol. Exp. Ther. 271:1994;100-106.
160. Nowakowska E., Chodera A., Kus K. An anxiolytic-like effect of ondansetron disappears in oxazepam-tolerant rats. Pharmacol. Biochem. Behav. 59:1998;935-938.
161. Olivier B., Molewijk H.E., Van Oorschot R., Van der Heyden J.A.M., Ronken E., Mos J. Rat pup ultrasonic vocalization: effects of benzodiazepine receptor ligands. Eur. J. Pharmacol. 358:1998;117-128.
162. Olivier B., Molewijk H.E., Van Oorschot R., Ronken E., Mos J., Miczek K.A. Utrasonic vocalizations in rat pups: effects of serotonergic ligands. Neurosci. Biobehav. Rev. 23:1998;217-227.
163. Onavi E.S., Martin B.R. Neuropharmacological and physiological validatiopn of a computer-controlled two-compartment black and white test box for the assessment of anxiety. Prog. Neuro-psychopharmacol. Biol. Psychiat. 13:1989;963-976.
164. Ortells M.I., Lunt G. Evolutionary history of the ligand-gated ion-channel superfamily of receptors. Tr. Neurosci. 18:1995;121-127.
165. 3 antagonists do not alter the discriminative stimulus properties of cocaine. Psychopharmacology. 104:1991;475-478.
166. Pellow S., Johnston A.L., File S.E. Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG7142 using the elevated plus-maze test in the rat. J. Pharm. Pharmacol. 39:1987;917-928.
167. Pinel J.P.J., Gorzalka B.B., Ladak F. Cadaverine and putrescine initiate the burial of dead conspecifics by rats. Physiol. Behav. 27:1981;819-824.
168. Pinel J.P.J., Treit D. Burying as a defensive response in the rat. J. Comp. Physiol. Psychol. 92:1978;708-712.
169. Pinel J.P.J., Treit D., Wilkie D.M. Stimulus control of defensive burying in the rat. Learn Motivation. 11:1980;150-163.
170. 3 recognition sites by its (R) and (S) enantiomers. Eur. J. Pharmacol. 179:1990;231.
171. 3 receptor antagonists BRL 43694 and GR38032F in animal behavioural models of anxiety. Br. J. Pharmacol. 94:1988;314P.
172. Poole S., Stephanson J.D. Core temperature: some shortcomings of rectal temperature measurements. Physiol. Behav. 18:1977;203-205.
173. 3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats. Naunyn-Schmiedeberg's. Arch. Pharmacol. 347:1993;111-114.
174. Richardson B.P., Engel G., Donatsch P., Stadler P.A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature. 316:1985;126-131.
175. 3 receptor antagonists in development as anxiolytics. Exp. Opin. Invest. Drugs. 4:1995;333-342.
176. Rocha e Silva M., Velle J.R., Picarelli Z.P. A pharmacological analysis of the mode of action of serotonin (5-HT) upon the guinea-pig ileum. Br. J. Pharmacol. 8:1953;378-388.
177. Rodgers, R.E., Cutler, M.G., Jackson, J.E., 1997a. Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol. Biochem. Behav. (in press).
178. 3 antagonists and benzodiazepines: their comparative behavioural pharmacology, pp. 195-231.
179. 3 receptor antagonists, ondansetron and WAY100289 in the elevated plus-maze test of anxiety on mice. Psychopharmacology. 177:1995;306-312.
180. Rodgers R.J., Cutler M.G., Jackson J.E. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II The elevated Plus-maze. Pharmacol. Biochem. Behav. 56:1997;295-303.
181. Rodgers R.J., Randall J.I. Acute Non-opioid analgesia in defeated male mice. Physiol. Behav. 36:1986;947-950.
182. Rodgers R.J., Randall J.I. Resident's Scent: a critical factor in acute analgesic reaction to defeat experience in male mice. Physiol. Behav. 37:1986;317-322.
183. Rodgers R.J., Randall J.I. Are the analgesic effects of social defeat mediated by benzodiazepine receptors? Physiol. Behav. 41:1987;279-289.
184. Rodgers R.J., Randall J.I. Benzodiazepine ligands, nociception and 'defeat' analgesia in male mice. Psychopharmacology. 91:1987;305-315.
185. Rodgers R.J., Randall J.I. Blockade of non-opioid analgesia in intruder mice by selective neuronal and non-neuronal benzodiazepine recognition site ligands. Psychopharmacology. 96:1988;45-54.
186. 3 antagonists on defeat analgesia. Br. J. Pharmacol. 100:1990;415P.
187. 3 receptor antagonist, GR38032F, on non-opiod defeat analgesia in male mice. Neuropharmacology. 29:1990;17-23.
188. 3 antagonist in benzodiazepine discontinuation. J. Clin. Psychopharmacol. 18:1998;121-131.
189. Saito H., Matsumoto M., Togashi H., Yoshioka M. Functional interaction between serotonin and other neuronal systems: Focus on in vivo microdialysis studies. Jap. J. Pharmacol. 70:1996;203-225.
190. Sanchez C. Effects of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats. Behav. Pharmacol. 4:1993;269-277.
191. Sanchez C., Arnt J., Hyttel J., Moltzen E.K. The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology. 110:1993;53-59.
192. 1A receptors play an important role in modulation of behavior of rats in a two-compartment black and white box. Pharmacol. 7:1996;788-797.
193. Schechter M.D. Cocaine discrimination is attenuated by isradipine and CGS 10746B. Pharmacol. Biochem. Behav. 44:1993;661-664.
194. Schneier F.R., Garfunkel R., Kennedy B., Campea R., Fallon B., Marshall R., O'Donnell L., Hogan T., Liebowitz M. Ondansetron in the treatment of panic disorder. Anxiety. 2:1996;199-202.
195. Schreiber R., Melon C., De Vrij J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology. 135:1998;383-391.
196. 1A-receptor ligand ipsapirone (TVX Q7821): a comparison with 8-OH-DPAT and diazepam. Psychopharmacology. 89:1987;S54.
197. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. 1991;365-376 John Wiley & Sons Ltd, Chichester.
198. Shepherd J.K., Rodgers R.J. 8-OH-DPAT specifically enhances feeding behaviour in mice: evidence from behavioural competition. Psychopharmacology. 101:1990;408-413.
199. 4 receptor antagonists on rat behaviour in the elevated plus-maze test. Eur. J. Pharmacol. 305:1996;219-222.
200. Slangen J.L. Drug discrimination and animal models. Olivier B., Mos J., Slangen J.L. Animal models in Psychopharmacology. 1991;359-373 Birkhäuser, Basel.
201. 3 receptor and antiobsessional effect. Human Psychopharmacol. 7:1992;291-292.
202. 3 antagonists as antiemetic agents in cancer chemotherapy. Exp. Opin. Invest. Drugs. 5:1996;389-407.
203. 3 receptors in the mediation of the ethanol interoceptive cue. Eur. J. Pharmacol. 309:1996;141-147.
204. Stein L., Wise C.D., Berger B.D. Antianxiety action of benzodiazepines: decrease in activity of serotonergic neurones in the punishment system. Garattini S., Mussini E., Randell L.O. Benzodiazepines. 1973;229-326 Raven Press, New York.
205. Stolerman I.P., Stephenson J.D., Rauch J.R. Classification of opioid and 5-hydroxytryptamine receptors by means of driscriminative drug effects. Neuropharmacology. 26:1987;867-875.
206. 3 receptor mRNA. Proc. Natl. Acad. Sci. USA. 90:1993;1430-1434.
207. Tornatzky W., Miczek K.A. Alcohol, anxiolytics and social stress in rats. Psychopharmacology. 121:1995;135-144.
208. Treit D. Animal models for the study of anti-anxiety agents: a review. Neurosci. Biobehav. Rev. 9:1985;203-222.
209. Treit D., Pinel J.P.J., Fibiger H.C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol. Biochem. Behav. 15:1981;619-626.
210. Tricklebank M.D. Behavioural correlates of the activation of 5-HT receptors. Mylecharane E.J., Angus J.A., De la Lande I.S., Humphrey P.P.A. Serotonin: Actions, receptors, pathophysiology. 1989;87-94 MacMillan, London, e.
211. 3 receptor antagonists in laboratory animals. Neurosci. Lett., Suppl. 29:1987;S68.
212. Unwin N. The structure of ion channels in membranes of excitable cells. Neuron. 3:1989;665-676.
213. 3 antagonist, reduce cocaine's psychomotor stimulant effects in the rat. Psychopharmacology. 101:1990;S59.
214. Van der Poel A.M., Noach E.J., Miczek K.A. Temporal patterning of ultrasonic distress calls in the adult rat: effects of morphine and benzodiazepines. Psychopharmacology. 97:1989;147-148.
215. Vivian J.A., Miczek K.A. Ultrasounds during morphine withdrawal in rats. Psychopharmacology. 104:1991;187-193.
216. Vivian J.A., Miczek K.A. Diazepam and gepirone selectively attenuate either 20-32 kHz or 32-64 kHz ultrasonic vocalizations during aggressive encounters. Psychopharmacology. 112:1993;66-73.
217. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
218. 3 receptors with high affinity in rat brain. Eur. J. Pharmacol. 181:1990;283-287.
219. White S.M., Kucharik R.F., Moyer J.A. Effects of serotonergic agents on isolation-induced aggression. Pharmacol. Biochem. Behav. 39:1991;729-736.
220. Wilde M.I., Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 52:1996;773-794.
221. Winslow J., Insel T.R. The infant rat separation paradigm: a novel test for novel anxiolytics. Tr. Pharmacol. Sci. 12:1991;402-404.
222. Yarker Y.E., McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs. 48:1994;761-793.
223. Ybema C., Slangen J.L., Olivier B., Mos J. Discriminative stimulus properties of the serotonergic compound eltoprazine. J. Pharmacol. Exp. Therap. 260:1992;1045-1051.
224. Ybema C., Van den Broek I., Slangen J.L., Olivier B., Mos J. Further characterization of the discriminative stimulus induced by flesinoxan. Olivier B., Mos J., Slangen J.L. Animal Models in Psychopharmacology. 1991;387-393 Birkhäuser, Basel.
225. Yocca F.D. Novel anxiolytic agents: actions on specific subtypes of central 5-HT receptors. Meldrum B.S., Williams M. Current and future trends in anticonvulsant, anxiety and stroke therapy. 1990;145-167 Wiley-Liss, New York.
226. Young R., Glennon R.A. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methyl serotonin discriminative stimulus. Eur. J. Pharmacol. 212:1992;117-119.
227. Young R., Johnson D.N. Anxiolytic-like activity of R(+)- and S(-)-zacopride in mice. Eur. J. Pharmacol. 201:1991;151-155.
228. Zethof T.J.J., Van der Heyden J.A.M., Olivier B. A new animal model for anticipatory anxiety. Olivier B., Manceaux A. Destructive drives and impulse control. Preclinical considerations. 1991;34-40 Solvay, Weesp.
229. Zethof T.J.J., Van der Heyden J.A.M., Tolboom J.T.B.M., Olivier B. Stress-induced hyperthermia in mice: a methodological study. Physiol. Behav. 55:1994;109-115.
230. Zethof T.J.J., Van der Heyden J.A.M., Tolboom J.T.B.M., Olivier B. Stress-induced hyperthermia as a putative anxiety model. Eur. J. Pharmacol. 294:1995;125-135.